Proactive - Interviews for investors
Poolbeg Pharma CEO says POLB-001 patent win strengthens Big Pharma partnership potential
Poolbeg Pharma CEO Jeremy Skillington discussed the company’s first national patent for POLB-001, granted by IP Australia. This patent, covering p38 MAPK inhibitors for treating cytokine release syndrome (CRS), strengthens the company's position in oncology and its potential for…